AnaCardio raises SEK 33 million for development of a novel therapy for heart failure
STOCKHOLM, SWEDEN - 3 February 2022: AnaCardio today announced the completion of a fundrasing round of 33 MSEK. The funds will be used to progress clinical development of its lead asset in heart failure. The capital injection is comprised of a convertible loan granted by Karolinska Development AB, LLD Nybohov Invest AB and Fredrik and Ann-Helene Ljungström. “We are pleased that these prominent investors want to continue supporting AnaCardio on its journey to improve the treatment options for heart failure patients. With this capital injection we are on-track to progress with our